Patents by Inventor Linda F. Thompson

Linda F. Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7094538
    Abstract: The lifetime probability of a person developing cancer can now be determined based on an allelic variation found in the 3?UTR of the prohibitin gene. The probability is dependent on the sequence of the 3?UTR at position 729, i.e., whether there is a thymine (T) or a cytosine (C) or both at this position. Determining the sequence at the position 729 can be done by any number of standard techniques. Preferably, the sequence is determined by amplifying this region by PCR and subjecting it to an RFLP analysis.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: August 22, 2006
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Eldon R. Jupe, Linda F. Thompson, Regina Resta, Robert T. Dell'Orco
  • Publication number: 20030073107
    Abstract: The lifetime probability of a person developing cancer can now be determined based on an allelic variation found in the 3′UTR of the prohibitin gene. The probability is dependent on the sequence of the 3′UTR at position 729, i.e., whether there is a thymine (T) or a cytosine (C) or both at this position. Determining the sequence at the position 729 can be done by any number of standard techniques. Preferably, the sequence is determined by amplifying this region by PCR and subjecting it to an RFLP analysis.
    Type: Application
    Filed: June 10, 2002
    Publication date: April 17, 2003
    Applicant: Oklahoma Medical Research Foundation
    Inventors: Eldon R. Jupe, Linda F. Thompson, Regina Resta, Robert T. Dell'Orco
  • Patent number: 6355427
    Abstract: The lifetime probability of a woman developing breast cancer can now be determined based on an allelic variation found in the 3′UTR of the prohibitin gene. The probability is dependent on the sequence of the 3′UTR at position 729, i.e., whether there is a thymine (T) or a cytosine (C) or both at this position. Polymorphism at position 729 is also disclosed as a susceptibility indicator for hereditary breast cancer in men. Determining the sequence at the position 729 can be done by any number of standard techniques. Preferably, the sequence is determined by amplifying this region by PCR and subjecting it to an RFLP analysis.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: March 12, 2002
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Eldon R. Jupe, Linda F. Thompson, Regina Resta, Robert T. Dell'Orco
  • Patent number: 4451570
    Abstract: Novel human lymphoblastoid cells and hybridomas derived therefrom are provided. The cells are a HGPRT negative human B-cell line. The cells are readily fusible with lymphoid cells to produce hybridomas which secrete human monoclonal antibodies.
    Type: Grant
    Filed: March 26, 1981
    Date of Patent: May 29, 1984
    Assignee: The Regents of the University of California
    Inventors: Ivor Royston, Harold Handley, J. Edwin Seegmiller, Linda F. Thompson